---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-24-000061"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:24:15.305008+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entrada Q3 net loss $14.0M; advancing DMD franchise with regulatory filings on track

## Summary
- Net loss $14.0M in Q3 2024 (vs $35.5M net income in Q3 2023); revenue down to $19.6M from $43.7M.
- Cash $449.3M as of Sep 30, 2024, up from $352.0M at end of 2023; funded by $100M offering and $75M milestone.
- R&D expenses $31.3M (vs $22.2M) driven by DMD candidates; G&A $10.0M (vs $7.5M).
- On track to submit global regulatory filings for Phase 2 trials of ENTR-601-44 and ENTR-601-45 in Q4 2024.
- Vertex completed SAD and initiated MAD for VX-670 in DM1; Sethuraman promoted to President of R&D.

## SEC filing metadata
- accession: 0001689375-24-000061
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000061/0001689375-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937524000061/trda-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-24-000061
- JSON: https://secwatch.observer/filing/0001689375-24-000061.json
- Plain text: https://secwatch.observer/filing/0001689375-24-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.